CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Corbus Pharmaceuticals Holdings, Inc. - CRBP CFD

5.284
3.12%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.332
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Corbus Pharmaceuticals Holdings Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 5.124
Open* 4.914
1-Year Change* 3895.12%
Day's Range* 4.884 - 5.604
52 wk Range 2.11-13.17
Average Volume (10 days) 23.25K
Average Volume (3 months) 257.85K
Market Cap 18.58M
P/E Ratio -100.00K
Shares Outstanding 4.42M
Revenue N/A
EPS -11.19
Dividend (Yield %) N/A
Beta 2.16
Next Earnings Date Mar 5, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 8, 2023 5.284 0.300 6.02% 4.984 5.604 4.734
Dec 7, 2023 5.124 -0.670 -11.56% 5.794 5.954 4.934
Dec 6, 2023 5.854 0.040 0.69% 5.814 6.084 5.804
Dec 5, 2023 6.054 0.490 8.81% 5.564 6.094 5.564
Dec 4, 2023 5.914 0.130 2.25% 5.784 6.034 5.594
Dec 1, 2023 6.064 0.080 1.34% 5.984 6.324 5.984
Nov 30, 2023 6.334 1.880 42.21% 4.454 6.334 4.454
Nov 29, 2023 4.694 0.820 21.17% 3.874 4.784 3.874
Nov 28, 2023 4.094 0.220 5.68% 3.874 4.184 3.874
Nov 27, 2023 4.134 0.020 0.49% 4.114 4.274 3.944
Nov 24, 2023 3.784 -0.180 -4.54% 3.964 4.144 3.784
Nov 22, 2023 3.904 -0.110 -2.74% 4.014 4.284 3.754
Nov 21, 2023 4.134 -0.110 -2.59% 4.244 4.464 4.114
Nov 20, 2023 4.294 0.280 6.98% 4.014 4.454 4.014
Nov 17, 2023 4.254 -0.130 -2.97% 4.384 4.424 4.054
Nov 16, 2023 4.164 0.100 2.46% 4.064 4.754 3.784
Nov 15, 2023 4.434 0.930 26.54% 3.504 4.714 3.414
Nov 14, 2023 3.624 0.330 10.02% 3.294 3.684 3.294
Nov 13, 2023 3.094 -0.120 -3.73% 3.214 3.454 2.864
Nov 10, 2023 3.094 -0.090 -2.83% 3.184 3.334 3.004

Corbus Pharmaceuticals Holdings, Inc. Events

Time (UTC) Country Event
Tuesday, March 5, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Corbus Pharmaceuticals Holdings Inc Earnings Release
Q4 2023 Corbus Pharmaceuticals Holdings Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0.88171 3.93723 36.1436 4.82227
Revenue 0 0.88171 3.93723 36.1436 4.82227
Total Operating Expense 39.8354 56.8707 126.747 113.248 61.57
Selling/General/Admin. Expenses, Total 18.6986 20.4254 28.4802 23.6434 12.956
Research & Development 16.1368 36.4453 98.2672 89.6048 48.614
Operating Income -39.8354 -55.989 -122.81 -77.1046 -56.7477
Interest Income (Expense), Net Non-Operating -2.46268 -1.5514 -1.72936 1.06902 1.07557
Net Income Before Taxes -42.3469 -45.6404 -111.269 -71.4537 -55.6721
Net Income After Taxes -42.3469 -45.6404 -111.269 -71.4537 -55.6721
Net Income Before Extra. Items -42.3469 -45.6404 -111.269 -71.4537 -55.6721
Net Income -42.3469 -45.6404 -111.269 -71.4537 -55.6721
Income Available to Common Excl. Extra. Items -42.3469 -45.6404 -111.269 -71.4537 -55.6721
Income Available to Common Incl. Extra. Items -42.3469 -45.6404 -111.269 -71.4537 -55.6721
Diluted Net Income -42.3469 -45.6404 -111.269 -71.4537 -55.6721
Diluted Weighted Average Shares 4.17068 4.09967 2.60444 2.12976 1.8998
Diluted EPS Excluding Extraordinary Items -10.1535 -11.1327 -42.7229 -33.5501 -29.3042
Diluted Normalized EPS -8.95464 -10.9849 -42.7229 -33.5501 -29.3042
Total Extraordinary Items
Other, Net -0.04877 11.9 13.2702 4.58184
Unusual Expense (Income) 5
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Total Operating Expense 8.18899 17.297 10.7968 8.18146 12.34
Selling/General/Admin. Expenses, Total 3.94029 3.90868 4.55406 4.07327 4.84037
Research & Development 4.24871 13.3883 6.24276 4.10819 2.49964
Operating Income -8.18899 -17.297 -10.7968 -8.18146 -12.34
Interest Income (Expense), Net Non-Operating -0.77751 -0.67729 -0.35778 -0.67798 -0.7002
Other, Net 0.18266 0.22951 0.27555 0.07771 -0.20868
Net Income Before Taxes -8.78384 -17.7448 -10.8791 -8.78172 -13.2489
Net Income After Taxes -8.78384 -17.7448 -10.8791 -8.78172 -13.2489
Net Income Before Extra. Items -8.78384 -17.7448 -10.8791 -8.78172 -13.2489
Net Income -8.78384 -17.7448 -10.8791 -8.78172 -13.2489
Income Available to Common Excl. Extra. Items -8.78384 -17.7448 -10.8791 -8.78172 -13.2489
Income Available to Common Incl. Extra. Items -8.78384 -17.7448 -10.8791 -8.78172 -13.2489
Diluted Net Income -8.78384 -17.7448 -10.8791 -8.78172 -13.2489
Diluted Weighted Average Shares 4.2777 4.18156 4.15711 4.17561 4.1752
Diluted EPS Excluding Extraordinary Items -2.0534 -4.24359 -2.61698 -2.1031 -3.17324
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -2.0534 -4.24359 -2.61698 -2.1031 -1.97569
Unusual Expense (Income) 0 0 0 5
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 60.1811 100.205 92.0746 38.1547 44.2403
Cash and Short Term Investments 59.197 97.6471 85.4334 31.7487 41.7485
Cash 3.80516 6.75159 1.82578 0.88412 0.80894
Cash & Equivalents 13.1976 18.255 83.6077 30.8646 40.9395
Total Receivables, Net 0 2.57833 2.68107
Prepaid Expenses 0.79162 2.36501 3.71286 3.72493 2.49184
Other Current Assets, Total 0.19248 0.19248 0.35 0
Total Assets 66.3119 107.73 102.295 49.1425 46.9893
Property/Plant/Equipment, Total - Net 5.49807 7.00181 9.31636 10.9029 2.70521
Property/Plant/Equipment, Total - Gross 8.59129 9.37405 11.6652 12.3088 3.37179
Accumulated Depreciation, Total -3.09322 -2.37224 -2.34884 -1.40596 -0.66658
Other Long Term Assets, Total 0.63277 0.52381 0.90394 0.08497 0.04382
Total Current Liabilities 12.6399 17.0075 31.8978 34.8877 18.0893
Accounts Payable 2.17396 1.78228 7.38118 11.0914 6.34534
Accrued Expenses 7.28012 11.2303 23.0095 23.0437 9.85119
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 3.14899 3.86128 0.71016 0.75266 0.39431
Other Current Liabilities, Total 0.03687 0.13371 0.797 0 1.4985
Total Liabilities 33.3219 38.6222 57.02 42.9849 19.4652
Total Long Term Debt 15.9844 15.6363 18.029 0 0
Other Liabilities, Total 4.69756 5.97842 7.09317 8.09723 1.37589
Total Equity 32.99 69.108 45.2749 6.15757 27.5241
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.00042 0.01252 0.00989 0.00647 0.00573
Additional Paid-In Capital 425.196 418.892 349.358 198.975 148.889
Retained Earnings (Accumulated Deficit) -392.081 -349.734 -304.093 -192.824 -121.37
Total Liabilities & Shareholders’ Equity 66.3119 107.73 102.295 49.1425 46.9893
Total Common Shares Outstanding 4.1713 4.17395 3.29476 2.15555 1.90806
Accounts Receivable - Trade, Net 0 1.6183 2.68107
Long Term Debt 15.9844 15.6363 18.029
Short Term Investments 42.1943 72.6405
Other Equity, Total -0.12609 -0.06245
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 31.206 38.274 45.865 60.1811 67.3478
Cash and Short Term Investments 28.7332 36.5659 44.227 59.197 66.2292
Cash 1.99596 1.72889 2.89716 3.80516 3.80611
Cash & Equivalents 9.25284 6.62046 4.42728 13.1976 8.63754
Short Term Investments 17.4844 28.2166 36.9026 42.1943 53.7856
Total Receivables, Net
Accounts Receivable - Trade, Net
Prepaid Expenses 2.28026 1.51562 1.44552 0.79162 0.92616
Other Current Assets, Total 0.19248 0.19248 0.19248 0.19248 0.19248
Total Assets 36.2834 43.7234 51.6453 66.3119 73.8306
Property/Plant/Equipment, Total - Net 4.39874 4.76002 5.12041 5.49807 5.87229
Property/Plant/Equipment, Total - Gross 7.80649 8.01496 8.39551 8.59129 8.78111
Accumulated Depreciation, Total -3.40775 -3.25494 -3.27509 -3.09322 -2.90883
Other Long Term Assets, Total 0.6787 0.68937 0.65986 0.63277 0.61048
Total Current Liabilities 31.5423 16.3859 14.3589 12.6399 17.4692
Accounts Payable 4.71353 1.50573 1.32299 2.17396 1.37422
Accrued Expenses 8.94237 7.77604 7.78697 7.28012 6.07764
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 17.8496 7.06725 5.21212 3.14899 9.88364
Other Current Liabilities, Total 0.03687 0.03687 0.03687 0.03687 0.13371
Total Liabilities 35.9724 34.2028 35.1863 33.3219 31.8845
Total Long Term Debt 0.775 13.8194 13.9724 15.9844 9.38585
Long Term Debt 0.775 13.8194 13.9724 15.9844 9.38585
Other Liabilities, Total 3.65506 3.99753 6.85501 4.69756 5.02944
Total Equity 0.31102 9.52059 16.459 32.99 41.9461
Preferred Stock - Non Redeemable, Net 0 0
Common Stock 0.00044 0.00044 0.00042 0.00042 0.01253
Additional Paid-In Capital 428.981 428.153 426.352 425.196 423.342
Retained Earnings (Accumulated Deficit) -428.663 -418.609 -409.825 -392.081 -381.202
Other Equity, Total -0.00804 -0.02379 -0.06847 -0.12609 -0.20687
Total Liabilities & Shareholders’ Equity 36.2834 43.7234 51.6453 66.3119 73.8306
Total Common Shares Outstanding 4.42368 4.42368 4.21513 4.1713 4.17561
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -42.3469 -45.6404 -111.269 -71.4537 -55.6721
Cash From Operating Activities -37.5444 -48.1837 -99.6857 -45.7207 -30.0673
Cash From Operating Activities 0.763 0.99982 1.12385 0.73938 0.49394
Non-Cash Items 8.06298 12.1534 13.6647 12.5179 8.10229
Cash Interest Paid 1.96958 1.74088 0.62915 0.02945 0.01044
Changes in Working Capital -4.02351 -15.6965 -3.20492 12.4757 17.0086
Cash From Investing Activities 30.0741 -73.4165 -0.48449 -2.74254 -2.30042
Capital Expenditures -0.01345 -0.05417 -0.48449 -2.74254 -2.30042
Cash From Financing Activities -0.53362 60.8234 154.875 38.4635 11.4197
Financing Cash Flow Items 0 -1.82044 -6.03942 -2.57155 -0.69018
Issuance (Retirement) of Stock, Net 0 62.5861 142.201 40.6771 12.0527
Issuance (Retirement) of Debt, Net -0.53362 0.05778 18.7135 0.35798 0.05719
Net Change in Cash -8.00392 -60.7768 54.7047 -9.99978 -20.948
Other Investing Cash Flow Items, Total 30.0876 -73.3624
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -17.7448 -42.3469 -31.4678 -22.6861 -9.43724
Cash From Operating Activities -15.115 -37.5444 -30.0895 -22.8444 -10.6153
Cash From Operating Activities 0.18187 0.763 0.5786 0.3878 0.19572
Non-Cash Items 1.22002 8.06298 6.78652 5.24585 2.75334
Cash Interest Paid 0.64146 1.96958 1.40721 0.88743 0.431
Changes in Working Capital 1.22795 -4.02351 -5.98672 -5.79193 -4.12716
Cash From Investing Activities 5.5497 30.0741 18.2944 24.2657 42.9622
Capital Expenditures 0 -0.01345 -0.01345 -0.01345 -0.01345
Other Investing Cash Flow Items, Total 5.5497 30.0876 18.3078 24.2791 42.9756
Cash From Financing Activities -0.11301 -0.53362 -0.76794 -0.65723 -0.32713
Financing Cash Flow Items 0 0 0 0
Issuance (Retirement) of Stock, Net 0.03706 0 0 0 0
Issuance (Retirement) of Debt, Net -0.15007 -0.53362 -0.76794 -0.65723 -0.32713
Net Change in Cash -9.67828 -8.00392 -12.563 0.76403 32.0197
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Ikarian Capital LLC Hedge Fund 4.3462 192260 0 2023-06-30 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.0567 179456 1 2023-06-30 LOW
Sio Capital Management, LLC Hedge Fund 3.3908 150000 0 2023-06-30 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.7993 79597 9069 2023-06-30 LOW
Boothbay Fund Management, LLC Investment Advisor/Hedge Fund 0.8585 37976 0 2023-06-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7429 32865 0 2023-06-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.7143 31600 17919 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.2979 13179 0 2023-06-30 LOW
Moran (Sean F) Individual Investor 0.1501 6642 -1 2023-03-24 LOW
Tekla Capital Management LLC Investment Advisor 0.1163 5143 0 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 0.0758 3353 -12 2023-06-30 LOW
Cohen (Yuval) Individual Investor 0.074 3274 -1 2023-03-24 LOW
Morgan Stanley & Co. LLC Research Firm 0.0716 3168 -319 2023-06-30 MED
Dorsey, Wright & Associates, LLC Investment Advisor/Hedge Fund 0.0578 2555 2555 2023-06-30 HIGH
Group One Trading, L.P. Research Firm 0.0462 2045 -220 2023-06-30 HIGH
T. Rowe Price Associates, Inc. Investment Advisor 0.0424 1876 0 2023-08-31 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.0368 1629 0 2023-06-30 LOW
Catlin (Avery W) Individual Investor 0.0354 1567 0 2023-03-24
RBC Capital Partners Investment Advisor 0.0342 1512 1512 2023-06-30 HIGH
Kingsbury Capital Investment Advisors, LLC Investment Advisor 0.0254 1123 1123 2022-09-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Corbus Pharmaceuticals Company profile

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. The company was founded in 2009 and is based in Norwood, Massachusetts.
Industry: Bio Therapeutic Drugs

500 River Ridge Drive
NORWOOD
MASSACHUSETTS 02062
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

XRP/USD

0.63 Price
-5.420% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

71.93 Price
+0.620% 1D Chg, %
Long position overnight fee -0.0204%
Short position overnight fee -0.0015%
Overnight fee time 22:00 (UTC)
Spread 0.030

Gold

1,999.31 Price
-0.260% 1D Chg, %
Long position overnight fee -0.0199%
Short position overnight fee 0.0117%
Overnight fee time 22:00 (UTC)
Spread 0.50

US100

16,049.90 Price
-0.160% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading